VectorBuilder, a global leader in gene delivery technologies and CDMO solutions, today announced MuteFree™ AAV, a ...
New expedited service line designed for biotechs with timeline constraints, launched in response to client demandCan accelerate timeline to GMP ...
The "Adeno-Associated Viral (AAV) Vector Market Industry Trends and Global Forecasts to 2035: Distribution by Type of Therapy, Therapeutic Area, Route of Administration, Scale of Operation and ...
DUBLIN--(BUSINESS WIRE)--The "Adeno Associated Virus Vector Manufacturing Market Size, Share & Trends Analysis Report By Scale Of Operations (Clinical, Commercial), By Method, By Application, By ...
The viral vector specialist SIRION Biotech has announced the signing of a preferred partnership agreement with Heidelberg University Hospital ...
The first vector-delivered gene therapies to receive FDA approval for clinical use were Luxturna,1 Spark Therapeutics’ vision loss cure, and Zolgensma,2 Novartis’ spinal muscular atrophy treatment.
SYDNEY, March 18, 2026 (GLOBE NEWSWIRE)-- Viral Vector Manufacturing Facility Pty Ltd (VVMF), Australia’s first commercial viral vector Contract Development and Manufacturing Organisation (CDMO), ...
Morning Overview on MSN
Compact CRISPR tool boosts in-body gene editing to 90% in lab tests
For the millions of people living with genetic diseases like muscular dystrophy and inherited liver disorders, one of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results